Prager, Diane
Memorial Sloan Kettering Cancer Center · Kaiser Permanente · The University of Texas MD Anderson Cancer Center · University of California, Los Angeles · Genentech · Dana-Farber Cancer Institute · Vanderbilt-Ingram Cancer Center
3 papers on CoChat
Most cited papers
- Verified
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 2,517
- Verified
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 1,490
- Verified
A phase II trial of irinotecan in hormone-refractory prostate cancer
Reese, D. M., Tchekmedyian, S., Chapman, Y., Prager, D., & Rosen, P. J. (1998) · Investigational New Drugs
Prostate Cancer Treatment and ResearchCancer therapeutics and mechanisms
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free